NUBEQA
As listed in the register: NUBEQA 300 mg, comprimé pelliculé
300 mg · comprimé pelliculé
- Prescription only
- Active substance
- Darolutamide
- Made by
- BAYER AG (ALLEMAGNE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Details
| Made by | BAYER AG (ALLEMAGNE) |
|---|---|
| Active substance | Darolutamide |
| Strength | 300 mg |
| Form | comprimé pelliculé |
| Route | orale |
| Dispensing (as stated by the register) | prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE · prescription initiale hospitalière annuelle · prescription initiale réservée à certains spécialistes · liste I · renouvellement non restreint · prescription réservée aux médecins compétents en CANCEROLOGIE |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/20/1432 |
| Name in the register | NUBEQA 300 mg, comprimé pelliculé |
| Packs | 7 plaquette(s) PVC-Aluminium de 16 comprimé(s) |
| CIS | 62384935 |
| CIP13 | 3400930203545 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).